Skip to content
1887

Access Microbiology open research platform logo Access Microbiology

Volume 5, Issue 11

Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccination Open Access

Abstract

We examined the 11 month longitudinal antibody decay among two-dose mRNA vaccinees, and identified factors associated with faster decay.

The study included samples from the COVID-19 Occupational Risk, Seroprevalence and Immunity among Paramedics (CORSIP) longitudinal observational study of paramedics in Canada. Participants were included if they had received two mRNA vaccines without prior SARS-CoV-2 infection and provided two blood samples post-vaccination. The outcomes of interest were quantitative SARS-CoV-2 antibody concentrations. We employed spaghetti and scatter plots (with kernel-weighted local polynomial smoothing curve) to describe the trend of the antibody decay over 11 months post-vaccine and fit a mixed effect exponential decay model to examine the loss of immunogenicity and factors associated with antibody waning over time.

This analysis included 652 blood samples from 326 adult paramedics. Total anti-spike antibody levels peaked on the twenty-first day (antibody level 9042 U ml) after the second mRNA vaccine dose. Total anti-spike antibody levels declined thereafter, with a half-life of 94 [95 % CI: 70, 143] days, with levels plateauing at 295 days (antibody level 1021 U ml). Older age, vaccine dosing interval <35 days, and the BNT162b2 vaccine (compared to mRNA-1273 vaccine) were associated with faster antibody decay.

Antibody levels declined after the initial mRNA series with a half-life of 94 days, plateauing at 295 days. These findings may inform the timing of booster vaccine doses and identifying individuals with faster antibody decay.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antibody levels , immunogenicity decay , mRNA COVID-19 vaccines , risk factors and SARS-CoV-2
Funding
This study was supported by the:
  • Michael Smith Health Research BC
    • Principle Award Recipient: NotApplicable
  • Government of Canada
    • Principle Award Recipient: NotApplicable
© 2023 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000678.v3
2023-11-28
2025-01-14
Loading full text...

Full text loading...

/deliver/fulltext/acmi/5/11/acmi000678.v3.html?itemId=/content/journal/acmi/10.1099/acmi.0.000678.v3&mimeType=html&fmt=ahah

References

  1. Pritchard E, Matthews PC, Stoesser N, Eyre DW, Gethings O et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. Nat Med 2021; 27:1370–1378 [View Article] [PubMed]
     [Google Scholar]
  2. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021; 397:1819–1829 [View Article] [PubMed]
     [Google Scholar]
  3. Zollner A, Watschinger C, Rössler A, Farcet MR, Penner A et al. B and T cell response to SARS-CoV-2 vaccination in health care professionals with and without previous COVID-19. EBioMedicine 2021; 70:103539 [View Article] [PubMed]
     [Google Scholar]
  4. Lin D-Y, Gu Y, Wheeler B, Young H, Holloway S et al. Effectiveness of covid-19 vaccines over a 9-month period in North Carolina. N Engl J Med 2022; 386:933–941 [View Article] [PubMed]
     [Google Scholar]
  5. Brisotto G, Muraro E, Montico M, Corso C, Evangelista C et al. IgG antibodies against SARS-CoV-2 decay but persist 4 months after vaccination in a cohort of healthcare workers. Clin Chim Acta 2021; 523:476–482 [View Article] [PubMed]
     [Google Scholar]
  6. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur 2021; 10:100208 [View Article] [PubMed]
     [Google Scholar]
  7. Herishanu Y, Avivi I, Levi S, Shefer G, Bronstein Y et al. Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. Blood Adv 2022; 6:148–151 [View Article] [PubMed]
     [Google Scholar]
  8. Pérez-Alós L, Armenteros JJA, Madsen JR, Hansen CB, Jarlhelt I et al. Modeling of waning immunity after SARS-CoV-2 vaccination and influencing factors. Nat Commun 2022; 13:1614 [View Article] [PubMed]
     [Google Scholar]
  9. Hatzakis A, Karabinis A, Roussos S, Pantazis N, Degiannis D et al. Modelling SARS-CoV-2 binding antibody waning 8 months after BNT162b2 vaccination. Vaccines 2022; 10:1–14 [View Article] [PubMed]
     [Google Scholar]
  10. Bayart J-L, Douxfils J, Gillot C, David C, Mullier F et al. Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers. Vaccines 2021; 9:1–12 [View Article] [PubMed]
     [Google Scholar]
  11. Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N Engl J Med 2021; 385:e84 [View Article] [PubMed]
     [Google Scholar]
  12. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med 2021; 27:1205–1211 [View Article] [PubMed]
     [Google Scholar]
  13. Cheetham NJ, Kibble M, Wong A et al. Antibody levels following vaccination against SARS-Cov-2: associations with post-vaccination infection and risk factors. medRxiv 20221–41
     [Google Scholar]
  14. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med 2021; 385:1474–1484 [View Article] [PubMed]
     [Google Scholar]
  15. Takita M, Yoshida T, Tsuchida T, Nakagama Y, Kido Y et al. Low SARS-CoV-2 antibody titers may be associated with poor clinical outcomes for patients with severe COVID-19. Sci Rep 2022; 12:9147 [View Article] [PubMed]
     [Google Scholar]
  16. Legros V, Denolly S, Vogrig M, Boson B, Siret E et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol 2021; 18:318–327 [View Article] [PubMed]
     [Google Scholar]
  17. Garcia-Beltran WF, Lam EC, Astudillo MG, Yang D, Miller TE et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 2021; 184:476–488 [View Article] [PubMed]
     [Google Scholar]
  18. Asamoah-Boaheng M, Goldfarb DM, Karim ME, OBrien SF, Wall N et al. The relationship between anti-spike SARS-CoV-2 antibody levels and risk of breakthrough COVID-19 among fully vaccinated adults. J Infect Dis 2023; 227:339–343 [View Article] [PubMed]
     [Google Scholar]
  19. Grunau B, O’Brien SF, Kirkham TL, Helmer J, Demers PA et al. A prospective observational cohort comparison of SARS-CoV-2 seroprevalence between paramedics and matched blood donors in Canada during the COVID-19 pandemic. Ann Emerg Med 2022; 80:38–45 [View Article] [PubMed]
     [Google Scholar]
  20. Ainsworth M, Andersson M, Auckland K, Baillie JK, Barnes E. Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infect Dis 2020; 20:1390–1400 [View Article] [PubMed]
     [Google Scholar]
  21. Grunau B, Tom J, Asamoah-Boaheng M, O’Brien SF, Drews SJ et al. Sensitivity of the elecsys nucleocapsid assay for the detection of preceding SARS-CoV-2 infections. Open Forum Infect Dis 2022; 9:ofac349 [View Article] [PubMed]
     [Google Scholar]
  22. Gajewicz-Skretna A, Kar S, Piotrowska M, Leszczynski J. The kernel-weighted local polynomial regression (KwLPR) approach: an efficient, novel tool for development of QSAR/QSAAR toxicity extrapolation models. J Cheminform 2021; 13:9 [View Article] [PubMed]
     [Google Scholar]
  23. Müller HG. Weighted local regression and kernel methods for nonparametric curve fitting. J Am Stat Assoc 1987; 82:231–238 [View Article]
     [Google Scholar]
  24. GraphPad Equation: Two phase decay; 2022 https://www.graphpad.com/guides/prism/latest/curve-fitting/reg_exponential_decay_2phase.htm accessed 20 September 2022
  25. Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for covid-19. N Engl J Med 2021; 384:2259–2261 [View Article] [PubMed]
     [Google Scholar]
  26. Okba NMA, Raj VS, Widjaja I, GeurtsvanKessel CH, de Bruin E et al. Sensitive and specific detection of low-level antibody responses in mild middle east respiratory syndrome coronavirus infections. Emerg Infect Dis 2019; 25:1868–1877 [View Article] [PubMed]
     [Google Scholar]
  27. Guo X, Guo Z, Duan C, Chen Z, Wang G et al. Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers. medRxiv 2020 [View Article]
     [Google Scholar]
  28. Zuiani A, Wesemann DR. Antibody dynamics and durability in coronavirus disease-19. Clin Lab Med 2022; 42:85–96 [View Article] [PubMed]
     [Google Scholar]
  29. Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med 2020; 383:2439–2450 [View Article] [PubMed]
     [Google Scholar]
  30. Singhal S, Kumar P, Singh S, Saha S, Dey AB. Clinical features and outcomes of COVID-19 in older adults: a systematic review and meta-analysis. BMC Geriatr 2021; 21:321 [View Article] [PubMed]
     [Google Scholar]
  31. Centers for Disease Control and Prevention (CDC) COVID-19 Risks and Vaccine Information for Older Adults; 2022 https://www.cdc.gov/aging/covid19/covid19-older-adults.html accessed 26 September 2022
  32. Australian Government-Department of Health and aged care Clinical recommendations for COVID-19 vaccines; 2022 https://www.health.gov.au/initiatives-and-programs/covid-19-vaccines/advice-for-providers/clinical-guidance/clinical-recommendations accessed 21 September 2022
  33. Centers for Disease Control and Prevention Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States; 2022 https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
  34. Ministry of Health Ontario COVID-19 Vaccine Booster Recommendations; 2022 https://www.health.gov.on.ca/en/pro/programs/publichealth/coronavirus/docs/vaccine/COVID-19_vaccine_third_dose_recommendations.pdf
  35. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2 antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA 2021; 326:1533–1535 [View Article] [PubMed]
     [Google Scholar]
  36. Wang L, Davis PB, Kaelber DC, Xu R. Volkow Comparison of mRNA-1273 and BNT162b2 Vaccines on Breakthrough SARS-CoV-2 Infections, Hospitalizations, and Death During the Delta-Predominant Period. JAMA 2022; 327:678–680 [View Article] [PubMed]
     [Google Scholar]
  37. Payne RP, Longet S, Austin JA, Skelly DT, Dejnirattisai W et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 2021; 184:5699–5714 [View Article] [PubMed]
     [Google Scholar]
  38. Grunau B, Goldfarb DM, Asamoah-Boaheng M, Golding L, Kirkham TL et al. Immunogenicity of extended mRNA SARS-CoV-2 vaccine dosing intervals. J Am Med Assoc 2022; 327:279 [View Article]
     [Google Scholar]
  39. Grunau B, Asamoah-Boaheng M, Lavoie PM, Karim ME, Kirkham TL et al. A higher antibody response is generated with A 6- to 7-week (vs standard) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine dosing interval. Clin Infect Dis 2022; 75:e888–e891 [View Article]
     [Google Scholar]
  40. Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S et al. Two-dose severe acute respiratory syndrome coronavirus 2 vaccine effectiveness with mixed schedules and extended dosing intervals: test-negative design studies from British Columbia and Quebec, Canada. Clin Infect Dis 2022; 75:1980–1992 [View Article] [PubMed]
     [Google Scholar]
  41. Rubin R. COVID-19 vaccine makers plan for annual boosters, but it’s not clear they’ll be needed. JAMA 2021; 326:2247–2249 [View Article] [PubMed]
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000678.v3
Loading
Eleven-month SARS-CoV-2 binding antibody decay, and associated factors, among mRNA vaccinees: implications for booster vaccination
Access Microbiology 5, 000678.v3 (2023); https://doi.org/10.1099/acmi.0.000678.v3
/content/journal/acmi/10.1099/acmi.0.000678.v3
/content/journal/acmi/10.1099/acmi.0.000678.v3
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error